Last reviewed · How we verify

Leukotriene Receptor Antagonist — Competitive Intelligence Brief

Leukotriene Receptor Antagonist (Leukotriene Receptor Antagonist) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Leukotriene receptor antagonist. Area: Respiratory / Immunology.

phase 3 Leukotriene receptor antagonist Cysteinyl leukotriene receptors (CysLT1, CysLT2) Respiratory / Immunology Small molecule Live · refreshed every 30 min

Target snapshot

Leukotriene Receptor Antagonist (Leukotriene Receptor Antagonist) — King Abdullah International Medical Research Center. Leukotriene receptor antagonists block cysteinyl leukotriene receptors on airway and immune cells, reducing inflammatory mediator signaling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Leukotriene Receptor Antagonist TARGET Leukotriene Receptor Antagonist King Abdullah International Medical Research Center phase 3 Leukotriene receptor antagonist Cysteinyl leukotriene receptors (CysLT1, CysLT2)
Singulair montelukast Merck & Co. marketed Leukotriene receptor antagonist (LTRA) Cytochrome P450 2C8, Adenosine receptor A3, Cysteinyl leukotriene receptor 2 1998-02-20
Accolate ZAFIRLUKAST Strides Pharma Intl marketed Leukotriene Receptor Antagonist [EPC] Cysteinyl leukotriene receptor 1 1996-01-01
Montelukast (Low FeNO group) Montelukast (Low FeNO group) Hull University Teaching Hospitals NHS Trust marketed Leukotriene receptor antagonist CysLT1 (cysteinyl leukotriene receptor type 1)
Montelukast,mometazon froat Montelukast,mometazon froat Istanbul Training and Research Hospital marketed Leukotriene receptor antagonist + inhaled corticosteroid combination Cysteinyl leukotriene receptor 1 (CysLT1) and glucocorticoid receptor
Montelukast placebo granüle Montelukast placebo granüle Kecioren Education and Training Hospital marketed Leukotriene receptor antagonist CysLT1 receptor
ICS/LABA and Montelukast ICS/LABA and Montelukast The First Affiliated Hospital of Guangzhou Medical University marketed ICS/LABA combination with leukotriene receptor antagonist Glucocorticoid receptor, beta-2 adrenergic receptor, cysteinyl leukotriene receptor (CysLT1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Leukotriene receptor antagonist class)

  1. Organon and Co · 2 drugs in this class
  2. Hull University Teaching Hospitals NHS Trust · 2 drugs in this class
  3. ALK-Abelló A/S · 1 drug in this class
  4. King Abdullah International Medical Research Center · 1 drug in this class
  5. SamA Pharmaceutical Co., Ltd · 1 drug in this class
  6. Kecioren Education and Training Hospital · 1 drug in this class
  7. GlaxoSmithKline · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Leukotriene Receptor Antagonist — Competitive Intelligence Brief. https://druglandscape.com/ci/leukotriene-receptor-antagonist. Accessed 2026-05-18.

Build your own brief

Pick any drug + add comparators: